Zobrazeno 1 - 10
of 37
pro vyhledávání: '"новые пероральные антикоагулянты"'
Autor:
A. V. Fonyakin, L. A. Geraskina
Publikováno v:
Медицинский совет, Vol 0, Iss 12, Pp 78-83 (2015)
Cardiocerebral embolism is responsible for the development of 30-40% of ischemic stroke events. [1-3] Apart from its high incidence, cardioembolic stroke (CEI) is often associated with significant residual impairment of motor, speech and coordination
Externí odkaz:
https://doaj.org/article/d31aca9f47124ffe97874ba769ba3d76
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 9, Iss 5, Pp 525-531 (2015)
The clinical significance of the patient genetic characteristics in the individual pharmacological response to oral anticoagulants is considered. Possible tactics of warfarin dosing and new oral anticoagulants choice on the basis of pharmacogenetic t
Externí odkaz:
https://doaj.org/article/189a689a3a01454b92e9d312b92fd397
Autor:
A. V. Rudakova, V. A. Parfenov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 10, Iss 3, Pp 275-282 (2015)
Background. For prevention of thromboembolic events in patients with non-valvular atrial fibrillation (NVAF) the following types of antithrombotic therapy are used: anticoagulant therapy with vitamin K antagonists (such as warfarin), antiplatelet the
Externí odkaz:
https://doaj.org/article/68dc57b562194a789db462f64a160da7
Autor:
E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 9, Iss 5, Pp 551-556 (2015)
Disadvantages of vitamin K antagonist warfarin and the benefits of new anticoagulants, including dabigatran etexilate, in the stroke prevention in patients with atrial fibrillation are considered. Factors that influence the choice of dabigatran dose
Externí odkaz:
https://doaj.org/article/5cc44adbbae74f068d1d2dfd33f7451a
Autor:
E. N. Bochanova
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 11, Iss 1, Pp 92-95 (2015)
A complex system of hemostasis regulation, insufficient data on drugs pharmacokinetics, multiple factors effecting treatment, including patient’s adherence to therapy, that can lead to the need for the dosage regimen specification are presented.
Externí odkaz:
https://doaj.org/article/171ceb904c754e2689dbff97faf34db3
ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 11, Iss 2, Pp 116-123 (2015)
Aim. To study the structure and incidence of the in-hospital anticoagulants prescription in patients at high risk of thromboembolic events (TEE) and to evaluate clinical characteristics of anticoagulated patients (by the example of the University Cli
Externí odkaz:
https://doaj.org/article/b548dc0e1f604b01ac4e05aaf063a1bb
Autor:
D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 11, Iss 2, Pp 209-216 (2015)
Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base of the efficacy in the prevention of ischemic stroke in patients with atrial fibrillation. The article is devoted to apixaban use in clinical practice: exami
Externí odkaz:
https://doaj.org/article/66ccb771d501455f8b3489d168248d67
Autor:
S. Y. Martsevich, A. R. Navasardyan, N. P. Kutishenko, A. V. Zakharova, V. P. Voronina, N. A. Dmitrieva, L. Yu. Lrozdova, A. V. Zagrebelnyy, O. V. Lerman, Yu. V. Lukina, G. V. Martynova, A. A. Nikulina, G. S. Ryazanova, A. Yu. Suvorov, S. N. Tolpygina
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 10, Iss 6, Pp 625-630 (2015)
Aim. To study in the PROFILE register the rate of new oral anticoagulants (NOAC) taking in patients with atrial fibrillation (AF) and to identify the factors influencing it.Material and methods. Patients with AF who applied to the Cardiology Center i
Externí odkaz:
https://doaj.org/article/ea4476ebf61143adafeb10a74d518d3a
Publikováno v:
Атеротромбоз, Vol 0, Iss 2, Pp 11-18 (2014)
В наши дни уже никто не обсуждает вопрос, касающийся необходимости ан-тикоагулянтной терапии у больных с фибрилляцией предсердий (ФП), е
Externí odkaz:
https://doaj.org/article/97ffe2be6a9743bea28dec572977ed67
Publikováno v:
Атеротромбоз, Vol 0, Iss 2, Pp 82-85 (2014)
Фибрилляция и трепетание предсердий представляют важные проблемы современной кардиологии. Частота этих патологий существенно возраст
Externí odkaz:
https://doaj.org/article/4b9111756b854296aa9c954759af229e